Valemetostat tosylate + T-DXd + Dato-DXd
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Feb 16, 2024 → Nov 1, 2028
NCT ID
NCT06244485About Valemetostat tosylate + T-DXd + Dato-DXd
Valemetostat tosylate + T-DXd + Dato-DXd is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06244485. Target conditions include Advanced Solid Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06244485 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor